Fig. 2: Analysis of SBR score components.
From: Determinants of response to CDK4/6 inhibitors in the real-world setting
a Kaplan–Meier analysis of progression-free survival comparing overall SBR score across all patients. p = 0.026 by log rank. b Kaplan–Meier analysis of progression-free survival comparing overall SBR score across patients taking AI. p = 0.0045 by log rank. c Kaplan–Meier analysis of progression-free survival comparing overall SBR score across patients taking fulvestrant. p = 0.51 by log rank. d Kaplan–Meier analysis of progression-free survival comparing Nuclear Pleomorphism across patients taking AI. p = 0.038 by log rank. e Kaplan–Meier analysis of progression-free survival comparing Tubular Differentiation across patients taking AI. p = 0.44 by log rank. f Kaplan–Meier analysis of progression-free survival comparing Mitotic Rate across patients taking AI. p = 0.0052 by log rank.
